StreetInsider.com News Articles

Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD

Wed, 24 Dec 2025 23:05:00 -0500

CRISPR-GNDM® platform achieves potent and specific activation of LAMA1 with therapeutic benefit in preclinical models
Favorable safety and pharmacodynamics demonstrated in non-human primates

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been published in the peer-reviewed journal Human Gene Therapy.

The publication highlights compelling preclinical evidence that Modalis’ proprietary CRISPR-GNDM® epigenome editing technology can safely and robustly activate the LAMA1 gene as a novel therapeutic strategy for LAMA2-related congenital muscular dystrophy (LAMA2-CMD), a severe pediatric neuromuscular

Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD

Wed, 24 Dec 2025 23:05:00 -0500

CRISPR-GNDM® platform achieves potent and specific activation of LAMA1 with therapeutic benefit in preclinical models
Favorable safety and pharmacodynamics demonstrated in non-human primates

Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD

Wed, 24 Dec 2025 23:05:00 -0500

CRISPR-GNDM® platform achieves potent and specific activation of LAMA1 with therapeutic benefit in preclinical models
Favorable safety and pharmacodynamics demonstrated in non-human primates

Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD

Wed, 24 Dec 2025 23:05:00 -0500

CRISPR-GNDM® platform achieves potent and specific activation of LAMA1 with therapeutic benefit in preclinical models
Favorable safety and pharmacodynamics demonstrated in non-human primates

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced its recognition as a top eight finalist in the prestigious XPRIZE Healthspan competition’s FSHD Bonus Prize and award of $250,000 for demonstrating a feasible solution to treat Facioscapulohumeral muscular dystrophy (FSHD) .

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Mon, 12 May 2025 19:35:00 -0500

XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, launched the $101 million, 7-year global XPRIZE Healthspan competition

JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy